AstraZeneca Collaboration Pays Silence Therapeutics $10 Million Milestone Payment


Silence Therapeutics plc AstraZeneca has nominated the first product candidate under its siRNA (short interfering RNA) collaboration and will pay Silence a $10 million option fee to advance development on an undisclosed program, according to SLN Silence” or “the Company.

Silence Therapeutics is creating a new generation of medications by using the body’s natural RNA interference, or RNAi, process to limit the expression of certain target genes considered to play a role in the pathophysiology of diseases with large unmet need.

quiet’s mRNAi GOLDTM platform can be utilized to generate siRNAs (short interfering RNAs) that precisely target and quiet disease-associated genes in the liver, representing a significant opportunity.

Silence’s fully owned product candidates include SLN360, which is being developed to treat a high and prevalent unmet medical need in decreasing cardiovascular risk in those born with high levels of lipoprotein(a), and SLN124, which is being developed to address hematological illnesses.

Silence also has continuing R&D collaborations with companies such as AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma.

Certain statements in this announcement are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws, including statements about the Company’s cash runway and forecast operating cash flow, the Company’s clinical and commercial prospects, regulatory approvals of the Company’s product candidates, potential partnerships or collaborations or payments under new and existing collaborations, the iniative’s clinical and commercial prospects, the iniative’s clinical and commercial prospects, the iniative’s clinical and commercial prospects,These forward-looking statements are not historical facts, but rather reflect the Company’s current industry assumptions, views, expectations, estimates, and forecasts. Forward-looking statements are identified by words such as anticipate, expect, intend, plan, believe, seek, estimate, and similar terms.

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including those risks identified in the Company’s most recent Admission Document and its Annual Report on Form 20-F filed with the United States Securities and Exchange Commission.

Related Stories